NBRC Pharmacology Practice Exam

Ipratropium bromide is classified as an anticholinergic bronchodilator. It works by inhibiting the action of acetylcholine at muscarinic receptors in bronchial smooth muscle, leading to bronchodilation. This mechanism is particularly beneficial for patients with chronic obstructive pulmonary disease (COPD) and asthma as it helps to reduce airway resistance and improve airflow.

Anticholinergic medications, including ipratropium bromide, are commonly used in respiratory therapy to relieve bronchospasm, especially in situations where beta-agonists may not be effective or in conjunction with them for enhanced bronchodilation. Understanding this classification is essential for effective pharmacological treatment of respiratory conditions, and it distinguishes ipratropium from other classes such as short-acting beta-agonists, corticosteroids, and leukotriene receptor antagonists, each of which has different mechanisms and applications in managing respiratory diseases.